Drug Discovery Weekly — 2026-10-05

The FDA's expedited IND pilot program opened applications this week to accelerate early-stage drug development, while Novartis signed a landmark $7.8 billion licensing deal with Chinese biotech Abogen—signaling major pharma's increasing reliance on Asian innovation amid mounting patent cliff pressures. Bepirovirsen for chronic hepatitis B approaches a critical October 26 PDUFA decision.

Expedited Review Reshapes Drug Development Timeline as Mega-Pharma Doubles Down on China Deals

FDA & Regulatory Decisions

Expedited IND Pilot Program — FDA

• Indication: Multiple therapeutic areas
• Significance: The FDA opened a new pilot program to shorten drug approval timelines, helping companies move faster into human testing. This addresses competitive pressures from countries like China and Australia in bringing drugs to market.
• Timeline: Applications now open; program designed to reduce early-stage development bottlenecks

2 sources

statnews.com

statnews.com

statnews.com

Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorde

Q3 2026 FDA Approvals — Multiple Sponsors

• Indication: Oncology, rare neurological diseases, immunologic conditions
• Significance: The FDA approved 22 novel drugs in Q3 2026, including enlicitide, daraxonrasib, and oveporexton, plus first-in-class therapies for multiple rare diseases. This acceleration reflects the regulatory agency's commitment to faster pathways despite administrative changes.
• Timeline: Approvals finalized; labels under ongoing review for additional indications

Pierre Fabre Rare Disease Drug Resubmission — Pierre Fabre

• Indication: Undisclosed rare disease
• Significance: Pierre Fabre refiled after FDA agreement on regulatory pathway adjustments, demonstrating collaborative approach to rare disease development.
• Timeline: Resubmission in progress

Ibtrozi Label Expansion — Nuvation Bio

• Indication: CNS-active oncology condition
• Significance: FDA approved 14 months of additional follow-up data for the oral tyrosine kinase inhibitor, supporting broader clinical use and durability claims.
• Timeline: Label update approved

Pharma Deals & M&A

• Licensing Deal: Novartis + Abogen — $7.8 billion agreement in early October. Novartis licensed innovation from China-based Abogen, reflecting Western pharma's strategic pivot toward sourcing early-stage assets from Asian biotech as patent cliffs loom and R&D productivity stalls. Q3 2026 saw major pharma accelerate dealmaking to rebuild pipelines.

• Research Collaboration: Eli Lilly + InnoCare Pharma — $3.35 billion upfront payment for multi-target discovery and licensing agreement. Eli Lilly committed to funding research against five undisclosed targets, providing InnoCare with substantial capital for early-stage programs.

AI & Computational Drug Discovery

• Current Clinical Pipeline: Between 70-90 AI-designed or AI-substantially-assisted drug candidates have entered human clinical trials as of mid-2026, with at least one candidate in Phase IIa showing encouraging efficacy. However, at least one AI-selected candidate stalled in Phase I due to safety signals, underscoring the dual-edged nature of AI-guided discovery.

• Clinical Translation Challenges: A June 2026 Frontiers review covering reports from January 2007 to April 2026 revealed that AI excels at earlier adverse effect detection in toxicity assessments but faces persistent hurdles: biological complexity, fragmented data, and a shortage of scientists fluent in both machine learning and pharmaceutics remain barriers to broader clinical adoption.

Pipeline Watch: Key Upcoming Catalysts

• October 26, 2026: Bepirovirsen PDUFA Decision (Ionis Pharmaceuticals) — First hepatitis B antiviral therapy targeting disease progression; approval would reshape chronic HBV treatment landscape and validate oligonucleotide drug class for viral hepatology

• November 2026 (estimated): Multiple Oncology Readouts — Several Phase 2/3 trials in solid tumors and hematologic malignancies nearing data lock; expect announcements on gedatolisib successors and combination immunotherapies

• Q4 2026: Retatrutide BLA Filing Preparation (Eli Lilly) — Lilly plans Q1 2027 biological license application submission; TRIUMPH-1, -2, and -3 data reported; approval window late 2027–2028 for triple GLP-1/GIP/glucagon agonist in obesity

Week in Context

The week's regulatory and dealmaking activity underscores a fundamental strategic reset in global pharma. The FDA's new expedited IND program signals domestic confidence in faster development pathways, yet simultaneously, the $7.8 billion Novartis-Abogen deal reveals that Western companies now view China as a primary source of de novo innovation. This paradox reflects two pressures colliding: patent cliffs threatening pipelines and a recognition that internal R&D productivity has plateaued in several traditional therapeutic areas.

Bepirovirsen's upcoming PDUFA decision carries disproportionate weight. A hepatitis B approval would validate not just Ionis' antisense platform but also demonstrate the FDA's willingness to greenlight older, non-immunotherapy modalities for infectious diseases—potentially unlocking a new category of underexploited indications.

AI-in-drug-discovery metrics show maturation but sobering real-world constraints. While 70–90 candidates in trials is impressive numerically, the safety failures and clinical translation bottlenecks reported in 2026 literature suggest that AI's role remains computational assistance rather than autonomous discovery. The shortage of hybrid ML-pharma talent and the complexity of translating algorithmic predictions into human efficacy remain decisive limiters. Expect 2027 to focus less on how many AI candidates advance and more on which mechanisms prove clinically actionable.